The recommended dose is Silodosin 8 mg orally once daily with a meal.
Rapiflo, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Rapiflo is not indicated for the treatment of hypertension.
Silodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule and prostatic urethra. Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.
The recommended dose is Silodosin 8 mg orally once daily with a meal. 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment (CrCl 30-50 mL/min).
Strong P-glycoprotein inhibitors (e.g., cyclosporine): Co-administration may increase plasma Rapiflo concentration. Concomitant use of PDE5 inhibitors with alpha-blockers including Rapiflo can potentially cause symptomatic hypotension.
Patients with severe renal & hepatic impairment, concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir) and patients with a history of hypersensitivity to Silodosin.
Most common adverse reactions are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis and nasal congestion.
BPH/ Urinary retention/ Urinary incontinence
Store at below 30°C in a dry place protected from light. Keep out of reach of Children.
